Spruce Biosciences, Inc.

NASDAQ:SPRB

Biotechnology

Healthcare
$40.84 +5.07%

+$2.47 today

Market cap
$117.37M
Beta
3.20
P/E (TTM)
-1.9
EPS (TTM)
-$27.11
52W Low $7.00High $838.13

Volume 0.06M

Average 0.06M

SPRB Debt Repayment

Cash used to repay borrowings during the period.

Spruce Biosciences, Inc.NASDAQ: SPRB

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment turns positive

Q1 FY2026 debt repayment was $14.15M, compared with -$405K a year earlier. Trailing-twelve-month debt repayment was $14.55M.

Context

  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $14.15M or moves back toward the trailing-twelve-month quarterly average of $3.64M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.15M+1063.3% QoQ
Last fiscal yearDec 2025
-$2.06M+26.8% YoY
LTMMar 2026
$14.55M+997.1% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3592.8%——
1 year+26.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(2.06M) USD
Year-over-year change
-26.8%

Debt Repayment vs competitors

How SPRB compares with its peers on the latest reported figures

  • SPRB's LTM Mar 2026 debt repayment of $14.55M is the 2nd largest of the 9 companies compared; the peer median is $164K.
  • Its year-over-year change of +997.1% is the highest of 6, against a peer median of -63.3%.
SPRB Competitors Peer median
Debt Repayment for SPRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$32.41M ——154.3%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$14.55M +997.1%——
CUECue Biopharma, Inc.LTM Mar 2026$3.5M -12.5%—10.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$3.23M -1764.2%+9.5%970.3%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$3.09M -63.3%-7.9%134.6%
OSTXOS Therapies IncorporatedLTM Mar 2026$1.84M +182.3%——
VTVTvTv Therapeutics Inc.LTM Mar 2026$328K —-21.4%0.9%
EQEquillium, Inc.LTM Mar 2026$0 ———
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding SPRB) $164K-63.3%-7.9%72.6%

Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.29M)(46.18M)(47.92M)(53.04M)(38.97M)
Depreciation & Amortization68K74K70K46K21K
Deferred Income Tax00000
Stock-Based Compensation3.96M3.63M4.62M5.35M2.57M
Change in Working Capital1.96M1.13M10.36M(8.57M)(724K)
Accounts Receivables00000
Inventory00000
Accounts Payables(805K)(1.4M)1.91M(2.04M)(352K)
Other Working Capital2.76M2.53M8.45M(6.53M)(372K)
Other Non-Cash Items434K(340K)(404K)249K3.77M
Operating Cash Flow(35.88M)(41.68M)(33.28M)(55.96M)(33.33M)
Capital Expenditures(93K)(8K)(7K)00
Acquisitions (Net)00000
Purchases of Investments(79.08M)(36.8M)(11.88M)00
Sales of Investments060.5M67.67M00
Other Investing Activities00000
Investing Cash Flow(79.17M)23.69M55.78M00
Debt Repayment220K0(1.62M)(1.62M)(2.06M)
Common Stock Issued0(201K)53.62M246K50M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities423K(40K)(2.85M)(246K)(4.53M)
Financing Cash Flow643K(241K)49.14M(1.62M)43.48M
Effect of Forex Changes0187K000
Net Change in Cash(114.4M)(18.05M)71.64M(57.59M)10.15M
Free Cash Flow(35.97M)(41.69M)(33.28M)(55.96M)(33.33M)

Spruce Biosciences, Inc.

NASDAQ:SPRB

Intrinsic Alpha fair value

Locked

Current Price

$40.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.